{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:06Z","timestamp":1792512126481,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although most studies on the cardiovascular toxicity of proteasome inhibitors have focused on carfilzomib, the risk of cardiotoxicity associated with bortezomib remains controversial. This study aimed to evaluate the incidence and risk factors of cardiovascular adverse events (CVAEs) associated with bortezomib in patients with multiple myeloma in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included patients who were treated with bortezomib at a tertiary hospital in South Korea. CVAEs, defined as hypertension, arrhythmia, heart failure, myocardial infarction, pulmonary arterial hypertension, angina, and venous thromboembolism, were detected using cardiac markers, ECG, echocardiography, medications, or documentation by clinicians. The patients were observed for at least 6\u00a0months and up to 2\u00a0years after starting bortezomib administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 395 patients, 20.8% experienced CVAEs of any grade, and 14.7% experienced severe adverse events. The median onset time for any CVAE was 101.5 days\u00a0(IQR, 42\u2013182 days), and new-onset\/worsened hypertension was the most prevalent CVAE. The risk of CVAEs increased in patients with a body mass index lower than 18.5 (adjusted HR (aHR) 3.50, 95% confidence interval (CI) 1.05-11.72), light chain (1.80, 1.04-3.13), and IgD (4.63, 1.06-20.20) as the multiple myeloma subtype, baseline stroke (4.52, 1.59-12.80), and hypertension (1.99, 1.23-3.23). However, CVAEs did not significantly affect the 2-year overall survival and progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately 15% of the Korean patients treated with bortezomib experienced severe CVAEs. Thus, patients, especially those with identified risk factors, should be closely monitored for CVAE symptoms during bortezomib treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-024-00004-y","type":"journal-article","created":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T19:05:13Z","timestamp":1708283113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma"],"prefix":"10.1007","volume":"59","author":[{"given":"Bitna","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Nam","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju\u2011Yeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962\u201372.","journal-title":"Blood"},{"key":"4_CR2","unstructured":"Korea Central Cancer Registry, National Cancer Center, Ministry of Health and Welfare. Annual report of cancer statistics in Korea in 2018. 2020. (Accessed June 20, 2021, at http:\/\/ncc.re.kr\/cancerStatsList.ncc?searchKey=total&searchValue=&pageNum=1)."},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"4_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822\u20134.","journal-title":"Lancet"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875\u201383.","journal-title":"N Engl J Med"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050\u20133.","journal-title":"Blood"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, et al. Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies. JACC CardioOncol. 2023;5:1\u201321.","journal-title":"JACC CardioOncol"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561\u201384.","journal-title":"Cancer Metastasis Rev"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","volume":"16","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Callander NS, Alsina M, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018;16:11\u201320.","journal-title":"J Natl Compr Canc Netw"},{"key":"4_CR10","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma (Version 3.2023). (Accessed 20 June 2021, at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf)."},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","volume":"133","author":"P Efentakis","year":"2019","unstructured":"Efentakis P, Kremastiotis G, Varela A, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133:710\u201323.","journal-title":"Blood"},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hon.2959","volume":"40","author":"A Das","year":"2022","unstructured":"Das A, Dasgupta S, Gong Y, et al. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials. Hematol Oncol. 2022;40:233\u201342.","journal-title":"Hematol Oncol"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519.","journal-title":"JAMA Oncol"},{"key":"4_CR14","first-page":"961","volume":"13","author":"MK Gurram","year":"2017","unstructured":"Gurram MK, Pulivarthi S, Ehresmann K, Mathew J. Cardiotoxicity associated with bortezomib: a single-center experience. J Cancer Res Ther. 2017;13:961\u20133.","journal-title":"J Cancer Res Ther"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37:1946\u201355.","journal-title":"J Clin Oncol"},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","volume":"9","author":"Y Xiao","year":"2014","unstructured":"Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9:e87671.","journal-title":"PLoS ONE"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1002\/ajh.24599","volume":"92","author":"JC Reneau","year":"2017","unstructured":"Reneau JC, Asante D, van Houten H, et al. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: a propensity matched study of 1,790 patients. Am J Hematol. 2017;92:E15-17.","journal-title":"Am J Hematol"},{"key":"4_CR18","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9:3.","journal-title":"Med Sci (Basel)"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/bjh.14058","volume":"174","author":"D Robinson Jr","year":"2016","unstructured":"Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol. 2016;174:368\u201381.","journal-title":"Br J Haematol"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer C, Driessen C, Szabo Z, Mateos MV. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9:26.","journal-title":"Blood Cancer J"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3904\/kjm.2015.88.4.459","volume":"88","author":"J Song","year":"2015","unstructured":"Song J, Kim H, Shin S, Kim I, Oh D, Chong S. Reversible heart failure after bortezomib treatment in a patient with multiple myeloma. Korean J Med. 2015;88:459\u201363.","journal-title":"Korean J Med"},{"key":"4_CR22","unstructured":"US National Cancer Institute. Common terminology criteria for adverse events (CTCAE) (version 5.0). 2017. (Accessed 20 June 2021, at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf)."},{"key":"4_CR23","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487\u201398.","journal-title":"N Engl J Med"},{"key":"4_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2019.12.019","volume":"75","author":"NH Bishopric","year":"2020","unstructured":"Bishopric NH, Lippman ME. Adverse cardiovascular events in cancer trials: missing in action? J Am Coll Cardiol. 2020;75:629\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/bjh.14708","volume":"178","author":"JP Laubach","year":"2017","unstructured":"Laubach JP, Moslehi JJ, Francis SA, et al. A retrospective analysis of 3954 patients in phase 2\/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017;178:547\u201360.","journal-title":"Br J Haematol"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"e8769","DOI":"10.1097\/MD.0000000000008769","volume":"96","author":"D Park","year":"2017","unstructured":"Park D, Lee JH, Han S. Underweight: another risk factor for cardiovascular disease? a cross-sectional 2013 behavioral risk factor surveillance system (BRFSS) study of 491,773 individuals in the USA. Medicine (Baltimore). 2017;96:e8769.","journal-title":"Medicine (Baltimore)"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0025-6196(11)62336-7","volume":"77","author":"M Nakamura","year":"2002","unstructured":"Nakamura M, Satoh M, Kowada S, et al. Reversible restrictive cardiomyopathy due to light-chain deposition disease. Mayo Clin Proc. 2002;77:193\u20136.","journal-title":"Mayo Clin Proc"},{"key":"4_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2011-06-358895","volume":"119","author":"MA Gertz","year":"2012","unstructured":"Gertz MA, Buadi FK, Hayman SR, et al. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012;119:44\u20138.","journal-title":"Blood"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285\u201392.","journal-title":"Hypertension"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCRESAHA.116.308398","volume":"120","author":"AK Boehme","year":"2017","unstructured":"Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120:472\u201395.","journal-title":"Circ Res"},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1080\/10428194.2022.2084729","volume":"63","author":"M Ho","year":"2022","unstructured":"Ho M, Moscvin M, Low SK, et al. Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. Leuk Lymphoma. 2022;63:2403\u201312.","journal-title":"Leuk Lymphoma"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/clc.20904","volume":"34","author":"V Feliz","year":"2011","unstructured":"Feliz V, Saiyad S, Khan M, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34:356\u20139.","journal-title":"Clin Cardiol"},{"key":"4_CR33","doi-asserted-by":"crossref","unstructured":"Yanamandra U, Gupta S, Khadwal A, et al. Melphalan-induced cardiotoxicity: ventricular arrhythmias. BMJ Case Rep. 2016;2016:bcr2016218652.","DOI":"10.1136\/bcr-2016-218652"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/2042098612452291","volume":"3","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012;3:255\u201366.","journal-title":"Ther Adv Drug Saf"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-024-00004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-024-00004-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-024-00004-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T19:15:42Z","timestamp":1708283742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-024-00004-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s44313-024-00004-y","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}